Prostate Active Surveillance Study

Description

The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.

Conditions

Prostatic Neoplasms

Talk to us

Study Overview

On this page

Study Details

Study overview

The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.

Canary Prostate Active Surveillance Study

Prostate Active Surveillance Study

Condition
Prostatic Neoplasms
Intervention / Treatment

-

Contacts and Locations

San Francisco

Veterans Affairs San Francisco Health Care System, San Francisco, California, United States, 94121

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Stanford

Stanford University, Stanford, California, United States, 94305

Atlanta

Emory University, Atlanta, Georgia, United States, 30322

Boston

Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts, United States, 02215

Ann Arbor

University of Michigan, Ann Arbor, Michigan, United States, 48105

San Antonio

University of Texas Health Science Center, San Antonio, San Antonio, Texas, United States, 78229

Norfolk

Eastern Virginia Medical School, Norfolk, Virginia, United States, 23502

Seattle

Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States, 98108

Seattle

University of Washington, Seattle, Washington, United States, 98195

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histologically confirmed adenocarcinoma of the prostate from a prostate biopsy.
  • * Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.
  • * No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).
  • * ECOG Performance Status 0 or 1.
  • * Patient has elected Active Surveillance as preferred management plan for prostate cancer.
  • * Patient consent has been obtained according to local Institutional Review Board for acquisition of research specimens.
  • * Patient is accessible and compliant for follow-up.
  • * Prostate cancer diagnosis cannot be more than 3 years prior to baseline visit date.
  • * No more than two prostate biopsies including the initial biopsy in which cancer was diagnosed.
  • * If cancer diagnosis is more than one year before enrollment, there must be two prostate biopsies including the initial biopsy in which cancer was diagnosed and a subsequent biopsy. The subsequent biopsy may occur on the same day as the baseline visit.
  • * Biopsies must have at least 10 cores.
  • * Unwillingness or inability to undergo serial prostate biopsy.
  • * History of other malignancies, except: adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer (Ta) or other solid tumors curatively treated with no evidence of disease for \> 5 years.

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Washington,

Daniel W. Lin, MD, PRINCIPAL_INVESTIGATOR, University of Washington

James D. Brooks, MD, PRINCIPAL_INVESTIGATOR, Stanford University

Martin E. Gleave, MD, PRINCIPAL_INVESTIGATOR, University of British Columbia

Michael Liss, MD, PRINCIPAL_INVESTIGATOR, University of Texas Health Science Center, San Antonio

Peter R. Carroll, MD, MPH, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Robert W. Given, MD, PRINCIPAL_INVESTIGATOR, Eastern Virginia Medical School

Andrew A Wagner, MD, PRINCIPAL_INVESTIGATOR, Beth Israel Deaconess Medical Center/Harvard Medical School

Todd M. Morgan, MD, PRINCIPAL_INVESTIGATOR, University of Michigan

Lisa F Newcomb, PhD, STUDY_DIRECTOR, Fred Hutchinson Cancer Research Center/University of Washington

Martin G. Sanda, MD, PRINCIPAL_INVESTIGATOR, Emory University

Matthew R. Cooperberg, MD, MPH, PRINCIPAL_INVESTIGATOR, Veterans Affairs San Francisco Health Care System

Atreya Dash, MD, PRINCIPAL_INVESTIGATOR, Veterans Affairs Puget Sound Health Care System

Study Record Dates

2032-09